OBI PHARMA, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59 TWD | -0.34% |
|
-2.16% | -14.99% |
| Sales 2022 | 4.71M 145K | Sales 2023 | 41.55M 1.28M | Capitalization | 15.91B 488M |
|---|---|---|---|---|---|
| Net income 2022 | -1.61B -49.54M | Net income 2023 | -1.05B -32.1M | EV / Sales 2022 | 2,410 x |
| Net cash position 2022 | 4.48B 137M | Net cash position 2023 | 2.24B 68.61M | EV / Sales 2023 | 329 x |
| P/E ratio 2022 |
-9.51
x | P/E ratio 2023 |
-15.2
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 66.15% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.34% | ||
| 1 week | -2.16% | ||
| Current month | -5.90% | ||
| 1 month | -4.84% | ||
| 3 months | -12.98% | ||
| 6 months | -27.61% | ||
| Current year | -14.99% |
1 week
58.00
60.60
1 month
58.0066.20
Current year
58.0073.00
1 year
58.0099.30
3 years
58.00143.00
5 years
58.00170.00
10 years
58.00755.00
| Managers | Title | Age | Since |
|---|---|---|---|
Heidi Wang
CEO | Chief Executive Officer | - | 23-06-01 |
Chih Chuan Chen
DFI | Director of Finance/CFO | - | - |
Kuo Lin Kao
AUD | Comptroller/Controller/Auditor | - | 17-10-19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ta Meng Tseng
BRD | Director/Board Member | 66 | 13-02-06 |
Chih Chuan Chen
DFI | Director of Finance/CFO | - | - |
Tai Chang Wang
BRD | Director/Board Member | 65 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +0.68% | - | |
| 0.00% | 34 M€ | +5.94% | - | |
| 0.00% | 389 M€ | +5.80% | - | |
| 0.00% | 39 M€ | +3.93% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 59 | -0.34% | 149,932 |
| 24-04-23 | 59.2 | +1.02% | 200,796 |
| 24-04-22 | 58.6 | +0.17% | 160,391 |
| 24-04-19 | 58.5 | -3.78% | 528,326 |
| 24-04-18 | 60.8 | +0.83% | 120,245 |
End-of-day quote Taipei Exchange, April 23, 2024
More quotes
OBI Pharma, Inc. is a Taiwan-based company principally engaged in the development of new pharmaceuticals. The Company mainly operates its businesses through the research and development of novel cancer and infectious disease therapies. It also develops next generation active immunotherapies to treat cancers, including lung, prostate, pancreatic, stomach and ovarian cancers. It is engaged in the development of OBI-822 (formerly OPT-822/821), an active immunotherapy new drug for metastatic breast cancer; the research and development of therapeutic vaccine OBI-833 for the treatment of new generation of cancers, as well as the development of cancer testing reagent OBI-868.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -14.99% | 414M | |
| +4.09% | 43.84B | |
| +46.45% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- 4174 Stock
